BioSpace News Archive

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.

Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.

Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab, an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster presentation at the European Society for Medical Oncology Asia Congress 2023 taken place from December 1-3.

Coherus BioSciences, Inc., announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug, a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress taking place December 6 – 8, 2023 at Palexpo Exhibition Centre in Geneva, Switzerland.

Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.

EVONETIX LTD, the company developing semiconductor scale technology to improve access to gene synthesis, announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc., a global semiconductor leader.

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Kaneka Corporation has acquired all shares of Japan Medical Device Technology Co., Ltd., a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.

CDR-Life Inc. announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy.

Syntec Optics today announced it will be presenting at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.